B Castelo1, D Viñal2, R Maseda3, L Ostios1, D Sánchez1, B García-Salvatierra4, M J Escámez5, L Martínez-Santamaría5, M Del Río5, M Mora-Rillo6, Y Vilches7, M J Beato8, J C López Gutiérrez4, N Romero9, C Santos9, J Miranda1, R de Lucas3. 1. Department of Medical Oncology, La Paz University Hospital, Paseo de la castellana 261, 28046, Madrid, Spain. 2. Department of Medical Oncology, La Paz University Hospital, Paseo de la castellana 261, 28046, Madrid, Spain. dvinallozano@gmail.com. 3. Department of Dermatology, La Paz University Hospital, Madrid, Spain. 4. Department of Plastic Surgery, La Paz University Hospital, Madrid, Spain. 5. Department of Bio-Engineering, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), IIS-Fundación Jiménez Díaz (IISFJD), CIBER on Rare Diseases (U714 CIBERER-ISCIII), Carlos III University, Madrid (UC3M), Madrid, Spain. 6. Infectious Diseases Unit, Internal Medicine Department, La Paz University Hospital IdiPAZ, Madrid, Spain. 7. Department of Palliative Care, La Paz University Hospital, Madrid, Spain. 8. Department of Pathology, La Paz University Hospital, Madrid, Spain. 9. DEBRA (Dystrophic Epidermolysis Bullosa Research Association), Madrid, Spain.
Abstract
BACKGROUND: Cutaneous squamous cell carcinoma (cSCC) is the leading cause of death in patients with recessive dystrophic epidermolysis bullosa (RDEB). We provide the management and prognosis of cSCC in RDEB patients at a Spanish reference center. MATERIALS AND METHODS: We retrospectively included patients with RDEB attended in La Paz University Hospital from November 1988 to October 2018. RESULTS: Fourteen patients developed at least one cSCC. Tumors were predominantly well differentiated. Nearly half of the tumors have recurred. Median time to first recurrence was 23.4 months (95% CI: 17.2-29.5). Five patients have developed distant metastases. Median overall survival (mOS) was 136.5 months since the diagnosis of the first cSCC (95% CI: 30.6-242.3). When distant metastases occurred, mOS was 6.78 months (95% CI: 1.94-11.61). CONCLUSIONS: cSCC is a life-threatening complication of RDEB patients. Although tumors are usually well differentiated, they tend to relapse. This is the first Spanish report of cSCC arising in RDEB patients.
BACKGROUND:Cutaneous squamous cell carcinoma (cSCC) is the leading cause of death in patients with recessive dystrophic epidermolysis bullosa (RDEB). We provide the management and prognosis of cSCC in RDEB patients at a Spanish reference center. MATERIALS AND METHODS: We retrospectively included patients with RDEB attended in La Paz University Hospital from November 1988 to October 2018. RESULTS: Fourteen patients developed at least one cSCC. Tumors were predominantly well differentiated. Nearly half of the tumors have recurred. Median time to first recurrence was 23.4 months (95% CI: 17.2-29.5). Five patients have developed distant metastases. Median overall survival (mOS) was 136.5 months since the diagnosis of the first cSCC (95% CI: 30.6-242.3). When distant metastases occurred, mOS was 6.78 months (95% CI: 1.94-11.61). CONCLUSIONS: cSCC is a life-threatening complication of RDEB patients. Although tumors are usually well differentiated, they tend to relapse. This is the first Spanish report of cSCC arising in RDEB patients.
Authors: Jo-David Fine; Leena Bruckner-Tuderman; Robin A J Eady; Eugene A Bauer; Johann W Bauer; Cristina Has; Adrian Heagerty; Helmut Hintner; Alain Hovnanian; Marcel F Jonkman; Irene Leigh; M Peter Marinkovich; Anna E Martinez; John A McGrath; Jemima E Mellerio; Celia Moss; Dedee F Murrell; Hiroshi Shimizu; Jouni Uitto; David Woodley; Giovanna Zambruno Journal: J Am Acad Dermatol Date: 2014-03-29 Impact factor: 11.527
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: J E Mellerio; S J Robertson; C Bernardis; A Diem; J D Fine; R George; D Goldberg; G B Halmos; M Harries; M F Jonkman; A Lucky; A E Martinez; E Maubec; S Morris; D F Murrell; F Palisson; E I Pillay; A Robson; J C Salas-Alanis; J A McGrath Journal: Br J Dermatol Date: 2015-11-07 Impact factor: 9.302
Authors: R A Schwartz; A P Birnkrant; D J Rubenstein; U Kim; G H Burgess; H L Stoll; S W Chai; G J Southwick; H Milgrom Journal: Cancer Date: 1981-02-01 Impact factor: 6.860
Authors: Rocío Maseda; Lucía Martínez-Santamaría; Rosa Sacedón; Nora Butta; María Del Carmen de Arriba; Sara García-Barcenilla; Marta García; Nuria Illera; Isabel Pérez-Conde; Marta Carretero; Eva Jiménez; Gustavo Melen; Alberto M Borobia; Víctor Jiménez-Yuste; Ángeles Vicente; Marcela Del Río; Raúl de Lucas; María José Escámez Journal: Front Med (Lausanne) Date: 2020-11-26
Authors: Susan J Robertson; Elizabeth Orrin; Manpreet K Lakhan; Gavin O'Sullivan; Jessie Felton; Alistair Robson; Danielle T Greenblatt; Catina Bernardis; John A McGrath; Anna E Martinez; Jemima E Mellerio Journal: Acta Derm Venereol Date: 2021-08-24 Impact factor: 3.875